Adoptive Cell Therapy for Nonhematologic Solid Tumors

The long-term benefits demonstrated by immunotherapy in select tumors have failed to generalize to most nonhematologic solid tumors. Adoptive cell therapy (ACT)-a treatment on the basis of the isolation and engineering of living T cells and other immune cells-has shown early clinical advances. ACT, through tumor-infiltrating lymphocyte therapy, has shown activity in traditionally immunogenic tumors such as melanoma and cervical cancers, and has the potential to improve immune reactivity in these tumor types where traditional therapies have failed. Engineered T-cell receptor and chimeric antigen receptor T-cell therapies have also shown activity in select nonhematologic solid tumors. Through receptor engineering, and improved understanding of tumor antigens, these therapies have the potential to target poorly immunogenic tumors to deliver long-lasting responses. Additionally, non-T-cell therapies such as natural killer-cell therapy may allow for allogeneic forms of ACT. Each form of ACT has trade-offs that will likely limit their application to specific clinical settings. Key challenges with ACT include the logistical challenges of manufacturing, accurate antigen identification, and the risk of on-target, off-tumor toxicity. The successes of ACT are built on decades of advances in cancer immunology, antigen identification, and cell engineering. With continued refinements in these processes, ACT may extend the benefits of immunotherapy to more patients with advanced nonhematologic solid tumors. Herein, we review the major forms of ACT, their successes, and strategies to overcome the trade-offs of current ACTs. This article reviews adoptive cell therapy for nonheme solid tumors and describes specific challenges of each modality, strategies to overcome resistance, and the promise for treating traditionally nonimmunogenic and resistant cancers.

Automated summary

The long-term benefits of immunotherapy have not extended to most nonhematologic solid tumors. Adoptive cell therapy has shown promising results in immunogenic tumors and has the potential to improve immune response in traditionally nonresponsive tumors. Challenges include manufacturing logistics, accurate antigen identification, and off-tumor toxicity risk. Continued advancements in cancer immunology and cell engineering may help extend the benefits of immunotherapy to more patients.